Keeping Clinical Development Strategy on Track Email

Keeping Clinical Development Strategy on Track: Early Decisions That Reduce Risk and Delays

Dear Victoria,

Clinical development strategy is shaped well before a study begins. Decisions around trial design, endpoint selection, data strategy, and regulatory planning can have a lasting impact on execution, adaptability, and milestone delivery.

In this on-demand webinar, experts from Thermo Fisher Scientific discuss how small and mid-sized biotechs can strengthen planning and reduce downstream risk through a more integrated approach.

The discussion explores how to:

Identify early sources of strategic and operational misalignment
Understand how clinical, data, and regulatory decisions affect execution later in development
Strengthen planning around key milestones, including first patient in
Assess how integrated operating models can improve visibility and reduce fragmentation

Meet the speakers from Thermo Fisher Scientific

Gerri Baer, MD, FAAP

Vice President, Strategic Scientific Solutions at PPD

TJ Stalvey

Vice President, Neurosciences at PPD

Ariel Berger, MPH

Executive Director, Integrated Solutions, Real-World Data & Scientific Solutions at PPD

Shyam Banuprakash

Vice President, Data Science & Data Delivery for Medical Imaging at Clario

Vanessa Elharrar, MD, MPH (Moderator)

Vice President and Global Medical Officer at PPD

Don’t want to receive these emails? No problem, simply click on the Unsubscribe link below.

By accessing this content, you are permitting Pharma Ignite or a third party to contact you regarding the content (by phone or email).